Value of entheseal ultrasonography and serum cartilage oligomeric matrix protein in the preclinical diagnosis of psoriatic arthritis

Clinical Medicine Insights: Arthritis and Musculoskeletal Disorders

Volumn 3, Issue , 2010, Pages 7-14

  Farouk, Hanan Mohamed ^a   Mostafa, Afaf Abdel Alim ^a   Youssef, Sahar S ^a   Elbeblawy, Moataz Mohammed Samy ^a   Assaf, Naglaa Youssef ^a   Elokda, El Sayed E ^a  

^a AIN SHAMS UNIVERSITY   (Egypt)

Author keywords

Cartilage oligomeric matrix protein; Entheseal ultrasound; Psoriasis; Psoriatic arthritis

Indexed keywords

CARTILAGE OLIGOMERIC MATRIX PROTEIN;

ACHILLES TENDON; ADULT; ARTICLE; CLINICAL EXAMINATION; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE ACTIVITY; DISEASE SEVERITY; ECHOGRAPHY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PROGNOSIS; PSORIASIS; PSORIATIC ARTHRITIS; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY;

EID: 77952391405     PISSN: None     EISSN: 11795441     Source Type: Journal    
DOI: 10.4137/cmamd.s4461     Document Type: Article

References (34)

1. Menter A, Gottlieb A, Feldman SR, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis, section 1. Overview of psoriasis and guide lines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol. 2008;58(5):826-50.
2. Kane D, Pathare S. Early psoriatic arthritis. Rheum Dis Clin N Am. 2005;31:641-57.
3. Wilson FC, Icen M, Crowson CS, McEvoy MT, Gabriel SE, Kremers HM. Time trends in epidemiology and characteristics of psoriatic arthritis over 3 decades: A population based study. J Rheumatol. 2009;36(2):361-7.
4. Rozenblit M, Lebwohl M. New biologics for psoriasis and psoriatic arthritis. Dermatol Ther. 2009;22(1):56-60.
5. Ruderman EM, Tambar S. Psoriatic arthritis: prevalence, diagnosis, and review of therapy for the dermatologist. Dermatol Clin. 2004;22(4):477-86.
6. Scarpa R, Cuocolo A, Peluso R, et al. Early psoriatic arthritis: the clinical spectrum. J Rheumatol. 2008;35:137-41.
7. Tseng S, Reddi AH, DiCesare PE. Cartilage oligomeric matrix protein (COMP): A biomarker of arthritis. Biomarker Insight. 2009;4:33-44.
8. Meenagh G, Filippucci E, Kane D, Taggart A, Grassi W. Ultrasonogrpahy in rheumatology: developing its potential in clinical practice and research. Rheumatology. 2007;46:3-5.
9. Filippucci E, De Angelis R, Salaffi F, Grassi W. Ultrasound, skin and joints in psoriatic arthritis. J Rheumatol. 2009;36(Suppl I):35-38.
10. Sturrock RD. Clinical utility of utlrasonography in spondyloarthropathies. Current Rheumatology Reports. 2009;11(5):317-20.
11. Hedbom E, Antonsson P, Hjerpe A. Cartilge matrix proteins. An Acidic oligomeric protein (COMP) detected only in cartilage. J Biol Chem. 1992;267:6132-6.
12. Morozzi G, Fabbroni M, Bellisai F, Pucci G, Galeazzi M. Cartilage oligomeric matrix protein level in rheumatic diseases: potential use as a marker for measuring articular cartilage damage and/or the therapeutic therapy of treatments. Ann NY Scand Sci. 2007;1108:398-407.
13. Skoumal M, Haberhauer G, Fink A, et al. Increased serum levels of cartilage oligomeric matrix protein in patients with psoriasis vulgaris: A marker for unknown peripheral joint involvement? Clin Exp Rehumatol. 2008;26:1087-90.
14. Posey KL, Hecht JT. The role of cartilage oligomeric matrix protein (COMP) in skeletal disease. Current Drug Targets. 2008;9(10):869-77.
15. Kelman A, Lui L, Yao W, Krumme A, Nevitt M, Lane NE. Association of higher levels of serum cartilage oligomeric matrix protein and N-telopeptide cross links with the development of radiographic hip osteoarthritis in elderly women. Arthritis Rheum. 2005;54:236-43.
16. Taylor W, Gladman D, Helliwell P. Classification criteria for psoriatic arthritis: development of new criteria from a large international study. Arthritis Rheum. 2006;54:2665-73.
17. Feldman SR, Krueger GG. Psoriasis assessment tools in clinical trials. Ann Rheum Dis. 2005;46(Suppl II):ii65-8.
18. Mease PJ, Antoni CE, Gladman DD, Taylor WJ. Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis. 2005;64(Suppl II):ii49-54.
19. Van der Heijde D, Sharp J, Wassenberg S, Gladman DD. Psoriatic arthritis imaging: a review of scoring methods. Ann Rheum Dis. 2005;64(Suppl II):ii61-4.
20. De Filippis LG, Caliri A, LoGullo R, et al. Ultrasonography in the early diagnosis of psoriasis-associated enthesopathy. Int J Tissue React. 2005;27(4):159-62.
21. Riente L, Sedie AD, Fillippucci E, et al. Ultrasound imaging for the rheumatologist IX. Ultrasound imaging in spondyloarthritis. Clin Exp Rheumatol. 2007;25:349-53.
22. Knapp RG, Miler MC. Clinical epidemiology and biostatistics. Harwal Publishing Company, 1992.
23. Atzeni F, Sarzi-Puttini P, Vena GA. Resistant cases of psoriatic arthritis: How to manage them. J Rheumatol. 2009;83(0):73-5.
24. Jones SM, Arma JB, Cohen MG, Lovell CR, Evison G, McHugh NJ. Psoriatic arthritis: outcome of disease subsets and relationship of joint disease to nail and skin disease. Br J Rheumatol. 1994;33(9):834-9.
25. McGonagle D, Conaghan PG, Emery P. Psoriatic arthritis: a unified concept twenty years on. Arthritis Rheum. 1999;42:1080-7.
26. Galluzzo E, Lischi DM, Taglione E, Lombardini F, Pasero G, Perri G. Sonographic analysis of the ankle in patients with psoriatic arthritis. Scand J Rheumatol. 2000;29:52-5.
27. Desimone C, Guerriero C, Giampietruzzi AR, Costantini M, Di-Gregorio F, Amerio P. Achilles tendinitis in psoriasis: clinical and sonographic findings. J Am Acad Dermatol. 2003;49:217-22.
28. Weiner SM, Jurenz S, Uhi M, et al. Ultrasonography in the assessment of peripheral joint involvement in psoriatic arthritis. Clin Rheumatol. 2008;27:983-9.
29. Ozçakar L, Cetin A, Inanici F, Kaymak B, Gurer CK, Kolemen F. Ultrasonographical evaluation of the Achilles tendon in psoriasis patients. Int J Dermatol. 2005;44:930-2.
30. Jung YO, Do JH, Kang HJ, et al. Correlation of sonographic severity with biochemical markers of synovium and cartilage in knee osteoarthritis patients. Clin Exp Rehumatol. 2006;24:253-9.
31. Gomez-Barrena E, Lindross L, Ceponis A. Cartilage oligomeric matrix protein (COMP) is modified by intra-articular liposomal clodronate in an experimental model of arthritis. Clin Exp Rheumatol. 2006;24:622-8.
32. Dragomir AD, Kraus VB, Renner JB. Serum cartilage oligomeric matrix protein and clinical signs and symptoms of potential pre-radiographic hip and knee pathology. Osteoarthritis Cartilage. 2002;10:687-91.
33. De Jong Z, Munneke M, Vilim V, et al. Value of serum cartilage oligomeric matrix protein as a prognostic marker of large joint damage in rheumatoid arthritis. Data from the RAPIT study. Rheumatology. 2008;47(6):868-71.
34. Fujikawa K, Kawakami A, Tamai M, et al. High serum cartilage oligomeric protein determines the subset of patients with early stage rheumatoid arthritis with high serum C-reactive protein, matrix metalloproteinase- 3, and MRI-proven bone erosion. J Rheumatol. 2009;36(6): 1126-9.